Lyon, October 15, 2019 – Theranexus, a biopharmaceutical company innovating in the treatment of neurological diseases and a pioneer in the development of drug candidates modulating the interaction between neurons and glial cells, today announces its cash position as of September 30, 2019.
Total available funds as of September 30, 2019 stood at €9,542,000 compared to €10,231,000 as of June 30, 2019, reflecting effective cost control. This excludes the French Research Tax Credit for 2018 (€1.7m), which was collected at the beginning of October.
|
Contacts THERANEXUS Thierry Lambert Chief Financial Officer investisseurs@theranexus.fr | ACTUS finance & communication Caroline Lesage / Théo Martin Investor Relations +33 (0)1 53 67 36 79 / +33 (0)1 53 67 36 75 theranexus@actus.fr |
FP2COM Florence Portejoie Media Relations + 33 (0)6 07 76 82 83 fportejoie@fp2com.fr |